Gut microbiota-derived ursodeoxycholic acid alleviates low birth weight-induced colonic inflammation by enhancing M2 macrophage polarization
Tóm tắt
Low birth weight (LBW) is associated with intestinal inflammation and dysbiosis after birth. However, the underlying mechanism remains largely unknown. In the present study, we aimed to investigate the metabolism, therapeutic potential, and mechanisms of action of bile acids (BAs) in LBW-induced intestinal inflammation in a piglet model. The fecal microbiome and BA profile between LBW and normal birth weight (NBW) neonatal piglets were compared. Fecal microbiota transplantation (FMT) was employed to further confirm the linkage between microbial BA metabolism and intestinal inflammation. The therapeutic potential of ursodeoxycholic acid (UDCA), a highly differentially abundant BA between LBW and NBW piglets, in alleviating colonic inflammation was evaluated in both LBW piglets, an LBW-FMT mice model, and a DSS-induced colitis mouse model. The underlying cellular and molecular mechanisms by which UDCA suppresses intestinal inflammation were also investigated in both DSS-treated mice and a macrophage cell line. Microbiomes were analyzed by using 16S ribosomal RNA sequencing. Fecal and intestinal BA profiles were measured by using targeted BA metabolomics. Levels of farnesoid X receptor (FXR) were knocked down in J774A.1 cells with small interfering RNAs. We show a significant difference in both the fecal microbiome and BA profiles between LBW and normal birth weight animals in a piglet model. Transplantation of the microbiota of LBW piglets to antibiotic-treated mice leads to intestinal inflammation. Importantly, oral administration of UDCA, a major BA diminished in the intestinal tract of LBW piglets, markedly alleviates intestinal inflammation in LBW piglets, an LBW-FMT mice model, and a mouse model of colitis by inducing M2 macrophage polarization. Mechanistically, UDCA reduces inflammatory cytokine production by engaging BA receptor FXR while suppressing NF-κB activation in macrophages. These findings establish a causal relationship between LBW-associated intestinal abnormalities and dysbiosis, suggesting that restoring intestinal health and postnatal maldevelopment of LBW infants may be achieved by targeting intestinal microbiota and BA metabolism.
Tài liệu tham khảo
McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. New Engl J Med. 1999;340(16):1234–8.
Zhu YH, Wang W, Yuan TL, Fu LL, Zhou LA, Lin G, et al. MicroRNA-29a mediates the impairment of intestinal epithelial integrity induced by intrauterine growth restriction in pig. Am J Physiol-Gastr L. 2017;312(5):G434–42.
Wu G, Bazer FW, Wallace JM, Spencer TE. Board-invited review: intrauterine growth retardation: implications for the animal sciences. J Anim Sci. 2006;84(9):2316–37.
Jain V, Singhal A. Catch up growth in low birth weight infants: striking a healthy balance. Rev Endocr Metab Disord. 2012;13(2):141–7.
Guilloteau P, Zabielski R, Hammon HM, Metges CC. Nutritional programming of gastrointestinal tract development. Is the pig a good model for man? Nutr Res Rev. 2010;23(1):4–22.
Roura E, Koopmans SJ, Lalles JP, Le Huerou-Luron I, de Jager N, Schuurman T, et al. Critical review evaluating the pig as a model for human nutritional physiology. Nutr Res Rev. 2016;29(1):60–90.
Wang XQ, Lin G, Liu C, Feng CP, Zhou HJ, Wang TJ, et al. Temporal proteomic analysis reveals defects in small-intestinal development of porcine fetuses with intrauterine growth restriction. J Nutr Biochem. 2014;25(7):785–95.
Wang JJ, Chen LX, Li DF, Yin YL, Wang XQ, Li P, et al. Intrauterine growth restriction affects the proteomes of the small intestine, liver, and skeletal muscle in newborn pigs. J Nutr. 2008;138(1):60–6.
Wang XQ, Wu WZ, Lin G, Li DF, Wu GY, Wang JJ. Temporal proteomic analysis reveals continuous impairment of intestinal development in neonatal piglets with intrauterine growth restriction. J Proteome Res. 2010;9(2):924–35.
Huang SM, Li N, Liu C, Li TT, Wang W, Jiang LL, et al. Characteristics of the gut microbiota colonization, inflammatory profile, and plasma metabolome in intrauterine growth restricted piglets during the first 12 hours after birth. J Microbiol. 2019;57(9):748–58.
Tao SY, Bai Y, Li TT, Li N, Wang JJ. Original low birth weight deteriorates the hindgut epithelial barrier function in pigs at the growing stage. Faseb J. 2019;33(9):9897–912.
Huang SM, Wu ZH, Li TT, Liu C, Han DD, Tao SY, et al. Perturbation of the lipid metabolism and intestinal inflammation in growing pigs with low birth weight is associated with the alterations of gut microbiota. Sci Total Environ. 2020;719:137382.
Willing BP, Van Kessel AG. Host pathways for recognition: establishing gastrointestinal microbiota as relevant in animal health and nutrition. Livest Sci. 2010;133(1-3):82–91.
Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4(6):478–85.
Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.
Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22–39.
He YY, Mao CX, Wen H, Chen ZY, Lai T, Li LY, et al. Influence of ad libitum feeding of piglets with bacillus subtilis fermented liquid feed on gut flora, luminal contents and health. Sci Rep. 2017;7(1):1–0.
Theriot CM, Bowman AA, Young VB. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. Msphere. 2016;1(1):e00045–15.
Zhang YC, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. Toxicol Appl Pharmacol. 2014;277(2):138–45.
Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–9.
Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biot. 2017;101(1):47–64.
Li N, Huang SM, Jiang LL, Wang W, Li TT, Zuo B, et al. Differences in the gut microbiota establishment and metabolome characteristics between low- and normal-birth-weight piglets during early-life. Front Microbiol. 2018;9:1798.
Li N, Huang SM, Jiang LL, Dai ZL, Li TT, Han DD, et al. Characterization of the early life microbiota development and predominant Lactobacillus species at distinct gut segments of low- and normal-birth-weight piglets. Front Microbiol. 2019;10:797.
Boehm G, Muller DM, Teichmann B, Krumbiegel P. Influence of intrauterine growth-retardation on parameters of liver-function in low-birth-weight infants. Eur J Pediatr. 1990;149(6):396–8.
Strandvik B. Bile-acid metabolism in low-birth-weight infants. Acta Paediatr Scand. 1982;71:71–4.
Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(10):6251–61.
Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile acids activated receptors regulate innate immunity. Front Immunol. 2018;9:1853.
Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R. Differential-effects of chenodeoxycholic and ursodeoxycholic acids on interleukin-1, interleukin-6 and tumor-necrosis-factor-alpha production by monocytes. Hepatology. 1992;16(3):719–23.
Inagaki T, Moschetta A, Lee YK, Peng L, Zhao GX, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. P Natl Acad Sci USA. 2006;103(10):3920–5.
Yin J, Li YY, Han H, Chen S, Gao J, Liu G, et al. Melatonin reprogramming of gut microbiota improves lipid dysmetabolism in high-fat diet-fed mice. J Pineal Res. 2018;65(4):e12524.
Maeda H, Fujimoto C, Haruki Y, Maeda T, Kokeguchi S, Petelin M, et al. Quantitative real-time PCR using TaqMan and SYBR Green for Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, tetQ gene and total bacteria. FEMS Immunol Med Microbiol. 2003;39(1):81–6.
Park YH, Kim N, Shim YK, Choi YJ, Nam RH, Choi YJ, et al. Adequate dextran sodium sulfate-induced colitis model in mice and effective outcome measurement method. J Cancer Prev. 2015;20(4):260–7.
Kostovcikova K, Coufal S, Galanova N, Fajstova A, Hudcovic T, Kostovcik M, et al. Diet rich in animal protein promotes pro-inflammatory macrophage response and exacerbates colitis in mice. Front Immunol. 2019;10:919.
Ma JL, Hong Y, Zheng NN, Xie GX, Lyu YZ, Gu Y, et al. Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically. Gut Microbes. 2020;11(5):1450–74.
Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–7.
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–+.
Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(D1):D590–6.
Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38(6):685–8.
Wang SL, Zhang SY, Huang SM, Wu ZH, Pang JM, Wu YJ, et al. Resistant maltodextrin alleviates dextran sulfate sodium-induced intestinal inflammatory injury by increasing butyric acid to inhibit proinflammatory cytokine levels. Biomed Res Int. 2020;2020:7694734.
Fan HN, Chen W, Zhu JS, Zhang J, Peng SQ. Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling. Int Immunopharmacol. 2019;76:105909.
Blake JA, Christie KR, Dolan ME, Drabkin HJ, Hill DP, Ni L, et al. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43(D1):D1049–56.
Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40(D1):D109–14.
Zhu W, Yu JB, Nie Y, Shi XK, Liu Y, Li FJ, et al. Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. Immunol Invest. 2014;43(7):638–52.
Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. Immunol Rev. 2014;260(1):102–17.
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–28.
Bozzetti V, Tagliabue PE, Visser GHA, van Bel F, Gazzolo D. Feeding issues in IUGR preterm infants. Early Hum Dev. 2013;89:S21–3.
Baserga M, Bertolotto C, Maclennan NK, Hsu JL, Pham T, Laksana GS, et al. Uteroplacental insufficiency decreases small intestine growth and alters apoptotic homeostasis in term intrauterine growth retarded rats. Early Hum Dev. 2004;79(2):93–105.
March MI, Gupta M, Modest AM, Wu LL, Hacker MR, Martin CR, et al. Maternal risk factors for neonatal necrotizing enterocolitis. J Matern-Fetal Neo M. 2015;28(11):1285–90.
Shang L, Tu J, Dai Z, Zeng X, Qiao S. Microbiota transplantation in an antibiotic-induced bacterial depletion mouse model: reproducible establishment, analysis, and application. Microorganisms. 2022;10(5):902.
Wang X, Tsai T, Deng F, Wei X, Chai J, Knapp J, et al. Longitudinal investigation of the swine gut microbiome from birth to market reveals stage and growth performance associated bacteria. Microbiome. 2019;7(1):109.
Zhao C, Hu X, Bao L, Wu K, Zhao Y, Xiang K, et al. Gut dysbiosis induces the development of mastitis through a reduction in host anti-inflammatory enzyme activity by endotoxemia. Microbiome. 2022;10(1):205.
Li N, Zuo B, Huang S, Zeng B, Han D, Li T, et al. Spatial heterogeneity of bacterial colonization across different gut segments following inter-species microbiota transplantation. Microbiome. 2020;8(1):161.
Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. 2019;12(4):851–61.
Fedorowski T, Salen G, Tint GS, Mosbach E. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology. 1979;77(5):1068–73.
Doden HL, Ridlon JM. Microbial hydroxysteroid dehydrogenases: from alpha to omega. Microorganisms. 2021;9(3):469.
Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology. 2002;36(3):525–31.
Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, Holvoet T, et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microbiol. 2017;83(7):e02766–16.
Ward JBJ, Lajczak NK, Kelly OB, O'Dwyer AM, Giddam AK, Gabhann JN, et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol-Gastr L. 2017;312(6):G550–8.
Loddenkemper C, Keller S, Hanski ML, Cao M, Jahreis G, Stein H, et al. Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int J Cancer. 2006;118(11):2750–7.
Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr-Us. 2004;145(3):317–21.
Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med J. 2006;47(2):147–51.
He Z, Ma Y, Yang S, Zhang S, Liu S, Xiao J, et al. Gut microbiota-derived ursodeoxycholic acid from neonatal dairy calves improves intestinal homeostasis and colitis to attenuate extended-spectrum beta-lactamase-producing enteroaggregative Escherichia coli infection. Microbiome. 2022;10(1):79.
Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593–604.
Liu YX, Liu X, Hua WW, Wei QY, Fang XJ, Zhao Z, et al. Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-kappa B signaling pathway to protect against DSS-induced colitis. Int Immunopharmacol. 2018;57:121–31.
Chen YS, Liu HM, Lee TY. Ursodeoxycholic acid regulates hepatic energy homeostasis and white adipose tissue macrophages polarization in leptin-deficiency obese mice. Cells. 2019;8(3):253.
Martinez-Moya P, Romero-Calvo I, Requena P, Hernandez-Chirlaque C, Aranda CJ, Gonzalez R, et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 2013;15(2):372–80.
Wang YD, Chen WD, Wang MH, Yu DN, Forman BM, Huang WD. Farnesoid X receptor antagonizes nuclear factor kappa B in hepatic inflammatory response. Hepatology. 2008;48(5):1632–43.
Gadaleta RM, Oldenburg B, Willemsen ECL, Spit M, Murzilli S, Salvatore L, et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kappa B signaling in the intestine. Bba-Mol Basis Dis. 2011;1812(8):851–8.
Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463–72.
Massafra V, Ijssennagger N, Plantinga M, Milona A, Pittol JMR, Boes M, et al. Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Bba-Mol Basis Dis. 2016;1862(2):166–73.
Ko WK, Lee SH, Kim SJ, Jo MJ, Kumar H, Han IB, et al. Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages. PLoS One. 2017;12(6):e0180673.
Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol. 2012;36:S3–S12.